- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Table of Contents

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 20, 2008

 

PharmaNet Development Group, Inc.

( Exact Name of Registrant as Specified in Charter)

 

Delaware		001-16119		59-2407464
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

504 Carnegie Center, Princeton, NJ 08540
(Address of Principal Executive Offices) (Zip Code)

[phone]
(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

þ		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 

---

TABLE OF CONTENTS

Item 8.01 Other Events
Item 9.01 Financial Statements and Exhibits
SIGNATURE
EX-99.1: PRESS RELEASE

---

Table of Contents

Item 8.01 Other Events.

     On November 20, 2008, PharmaNet Development Group, Inc. issued a press release announcing an exchange offer in which its outstanding 2.25% Convertible Senior Notes due 2024 may be exchanged for 8.00% Convertible Senior Notes due 2014 and cash. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated November 20, 2008.

 

---

Table of Contents

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November 20, 2008

	PHARMANET DEVELOPMENT GROUP, INC.
	By:	/s/ John P. Hamill
		Name:	John P. Hamill
		Title:	EVP and Chief Financial Officer